The trial sites will be able to automatically screen the participants based on PE and high right ventricular to left ventricular diameter ratio, using the platform. Credit: James Heilman, MD / commons.wikimedia.org.

Viz.ai has unveiled plans to use its Viz RECRUIT platform for optimising the enrolment of participants in the NIH-funded Pulmonary Embolism-Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial.

The randomised, open-label, assessor-blinded PE-TRACT trial has been designed to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in submassive pulmonary embolism (PE), proximal pulmonary artery thrombus, and right ventricular dilation patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will address whether CDT needs to be routinely used for the treatment of intermediate-risk PE compared to anticoagulants alone.

A total of 500 participants across 30 to 50 sites are planned to be enrolled in the trial.

In the trial, the participating research institutions will use the artificial intelligence (AI)-powered clinical trial enrolment platform, Viz RECRUIT, for finding, screening, and enrolling candidates in the clinical trial.

See Also:

The platform automates the identification of eligible candidates for pre-trial review and also reduces the burden on the research team.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition to streamlining the trial enrolment workflow, the Cloud-based technology also helps broaden the recruitment funnel in size and diversity.

The clinical trial sites will be able to automatically screen participants based on PE and high right ventricular to left ventricular diameter (RV/LV) ratio using the Viz RECRUIT platform.

Viz.ai chief clinical officer Jayme Strauss said: “With our platform’s real-world accuracy and demonstrated success, researchers can use AI to identify potentially eligible trial candidates, regardless of their location, ultimately expediting the clinical trial enrolment process.

“We aim to expand the participation and diversity of participants in clinical research to make treatments safer for all patients and advance the development of novel treatments while empowering research teams to efficiently and consistently screen for patients and coordinate research.”